[89Zr]Zr-p-NCS-Bz-DFO-anti-HER2 affibody

[89Zr]Zr-p-NCS-Bz-DFO-anti-HER2 affibody is a radiopharmaceutical consisting of a HER2-targeting affibody protein conjugated to the chelator p-NCS-Bz-DFO and radiolabeled with zirconium-89 (^89Zr^). The affibody binds specifically to the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain cancers, particularly breast cancer. Upon administration, the compound enables PET imaging of HER2-positive tumors, providing high contrast and specificity. The mechanism of action relies on the high-affinity binding of the affibody to HER2, with the radiolabel allowing sensitive detection and tracking. This agent is primarily intended for non-invasive imaging (immuno-PET) of HER2-positive malignancies, supporting diagnosis and monitoring of therapeutic response. It is currently under investigation, with in vitro and early in vivo studies demonstrating high stability and selective tumor uptake[1][2].

Other names

[89Zr]Zr-p-NCS-Bz-DFO-anti-HER2 affibody